How to Determine Product Classification for Overseas Registration of Dental Devices?

Executive Summary

Answer: The first step in overseas registration of dental devices is to accurately determine product classification, as it dictates the registration pathway, technical documentation requirements, depth of quality system review, and post-market surveillance intensity. Classification must not rely solely on China's NMPA classification, nor directly copy CE or FDA classifications. Instead, it must be confirmed country-by-country or region-by-region. Companies need to first verify whether the product falls within the target country's definition of a medical device, then determine the risk class according to classification rules, and finally assess whether existing NMPA, CE, FDA, ISO 13485 documentation can be reused. Different GHWP member states may classify the same product differently; for example, dental implants are typically managed as high-risk Class III or Class D, while dental handpieces may be managed as medium- or low-risk devices. In practice, companies also need to prepare technical documentation, clinical evaluation or literature evidence, labeling and instructions for use, local agent authorization, and initiate pre-review or request official classification rulings for products with unclear classification. Common risks include unrecognized classification differences leading to registration failure, delays, or post-market certificate revocation due to non-compliance with classification constraints. Therefore, companies must establish a classification determination process and leverage experienced local agents and regulatory consultants to ensure that overseas registration begins correctly from the outset.

Note: Compiled based on the AIMEILI registration practice database, medical device international registration knowledge base, and public regulatory information; specific projects should be based on the latest requirements of the target country's regulatory authority and the product documentation.

Applicable Scenarios and Core Questions

Dental devices cover a wide range: dental units, dental handpieces, ultrasonic scalers, dental implants, bone graft materials, abutments, orthodontic brackets, clear aligners, dental burs, impression materials, and denture repair materials, with vastly different risk levels. When companies initiate overseas registration, the first issue they encounter is not documentation, but "which classification does my product fall into in the target country?"

This determination directly affects the subsequent registration pathway: whether clinical data is required, whether a QMS on-site audit is needed, whether a local agent must submit the application, and the registration timeline and cost may differ by several times. Many companies mistakenly believe that obtaining a registration certificate in China or a CE certificate will automatically map to other countries, but the classification rules of GHWP member states are not uniform. For example, ion crowns may be Class IIa under ISO standards, but in some countries they may be classified as Class II or III.

Therefore, applicable scenarios include: companies preparing to enter markets such as Saudi Arabia, Indonesia, Thailand, Malaysia, the Philippines, Vietnam, Brazil, and Mexico and needing to clarify classification first; companies holding multiple domestic registration certificates and wanting to reuse technical documentation; or companies with existing CE certificates that need to reassess classification due to the MDR transition. The core questions are: What standard should be used? Who determines the classification, and when? And what are the consequences of incorrect classification?

When classification is unclear, companies must not guess or simply apply conclusions from other markets. They must review the target country's regulatory definitions and classification rules item by item. If necessary, they should request an official classification opinion from the regulatory authority before submission (e.g., the STAR system of the Saudi FDA, or the pre-classification system of the Indonesian MOH).

Classification Determination Logic

Determining the overseas classification of dental devices should follow a fixed logic: first confirm the regulatory scope, then determine the risk class, then compare existing evidence, and finally decide the registration pathway.

Step 1: Confirm whether the product falls within the scope of medical device regulation in the target country. Almost all GHWP countries treat invasive or implanted devices as medical devices, but certain oral care products with non-therapeutic purposes may be classed as ordinary consumer goods, such as toothbrushes and dental floss. If it is a consumer product, registration is not required, but labeling compliance should still be observed.

Step 2: Identify the classification rules of the target country. Most countries adopt a risk-based classification system. For example, Saudi Arabia classifies medical devices according to the MDMA classification, Brazil according to RDC 16/2013, and Southeast Asian countries generally refer to ASEAN or GHTF rules. Dental implants, absorbable materials, and dental materials containing active pharmaceutical ingredients are typically assigned to the highest risk category (Class III or Class D).

Step 3: Determine whether the company is eligible to apply. Most GHWP countries require overseas manufacturers to designate a local authorized representative or agent to submit the registration application and assume post-market responsibilities. The classification result determines the application pathway: high-risk devices require detailed technical documentation and expert review, while low-risk devices may only require self-declaration or abbreviated registration.

Step 4: Assess the reusability of existing documentation. Companies should organize existing NMPA registration certificates, CE certificates (or technical files), FDA 510(k)/PMA, ISO 13485 certificates, MDSAP certificates, etc. If the target country accepts these system documents, additional testing can be significantly reduced. However, when reusing, it is necessary to verify whether the technical parameters meet the target country's standards, as some countries have specific requirements for electrical safety or biocompatibility.

Step 5: Define the post-market maintenance requirements. The higher the classification, the stricter the post-market surveillance. Adverse event reporting, annual updates, and change approvals may all require the cooperation of a local agent. If the classification is incorrect, the registration certificate may be revoked or fines may be imposed. Therefore, confirmation with a consultant is essential at project initiation.

Documentation and Evidence

Classification determination is not based on speculation; it must be supported by documentation that proves the product's inherent risk attributes. Companies should prepare the following materials to support classification:

• Photographs, structural diagrams, composition, and working principle of the product
• Instructions for use, indications, and contraindications
• Registration certificates, CE certificates, or FDA certificates obtained in China or other markets
• ISO 13485 quality management system certificates and MDSAP certificates
• Risk management reports prepared in accordance with ISO 14971 (including risk analysis and risk evaluation)
• Biocompatibility test reports, such as ISO 10993 series tests
• Performance verification reports, such as mechanical performance, chemical performance, and sterilization validation
• Clinical evaluation reports or clinical literature data, especially for implantable products
• Draft labels and instructions for use, as well as packaging markings
• Declarations of conformity with classification-related standards, such as EN ISO standards

These materials not only demonstrate the safety and effectiveness of the product but also serve as the basis for regulatory authorities to judge the product's inherent risk level. For example, if a product is absorbable, it is likely to be classified as high-risk, and the company must provide toxicological analysis of degradation products in the risk management report.

For the CE pathway, classification is determined by the manufacturer according to MDCG 2021-24 guidance and included in the Declaration of Conformity; however, overseas countries often employ different classification determination procedures. Therefore, companies should not only prepare technical documentation but also create a classification comparison table for each market, explaining the classification differences and the basis for the same product in different countries.

If the target country requires pre-market consultation, companies should first submit classification consultation materials to obtain an official written opinion before proceeding with formal registration, avoiding unnecessary detours.

Common Mistakes

• Directly applying NMPA classification without verifying the target country's rules. For example, NMPA classifies light-cured resin as Class II, but in some Middle Eastern countries it may be classified as Class III.
• Relying solely on CE certificates without local assessment. MDR classification does not fully correspond with the classification of some GHWP countries; over-reliance on CE may lead to classification deviations.
• Ignoring the impact of intended use on classification. For a device with the same physical structure, the risk class may differ by two levels depending on whether it is used for short-term contact or implantation.
• Neglecting drug or animal-derived components in combination products. Dental materials containing antibiotic bone cement or decellularized animal tissue are often directly assigned to the highest risk category.
• Failing to distinguish between sterile and non-sterile states. Sterile devices require an additional layer of sterilization validation, but the classification may not change; companies often confuse this.
• Initiating registration without designating a local agent. Without a local agent, the applicant is ineligible, and classification pre-review cannot proceed.
• Incomplete documentation lists, missing labels and instructions for use directly related to classification, making it impossible to prove intended use.
• Not recording or reviewing classification results, leaving the company unable to provide justification when questioned by regulatory authorities.

Classification errors often only come to light during the technical documentation review stage. At that point, corrections not only extend the timeline but may also damage the trust relationship between the company and its agent.

Company Preparation Checklist

• Establish a cross-functional team including at least R&D, regulatory, quality, and marketing personnel.
• Collect official classification rules and product classification lists of the target country; do not use unofficial sources.
• Based on the product instructions and composition, document classification attributes such as intended use, contact type, contact duration, whether it is implanted, and whether it is absorbable.
• Perform a preliminary classification according to the target country's rules and record the basis for the determination.
• Organize existing certificates and test reports and assess whether they cover the target country's standards.
• Confirm the classification result with a local agent or regulatory consultant, and submit a pre-classification consultation if necessary.
• Prepare technical documentation according to the classification result, noting format requirements of different countries.
• Define the scope of authority of the local agent and control over certificates; establish change and renewal procedures.
• Develop a post-market surveillance plan, including adverse event reporting and annual updates.
• Periodically review the classification, especially when the product undergoes design or intended use changes.

This checklist should be embedded in the company's ISO 13485 system documents and linked to design and development inputs/outputs and risk management interfaces.

AIMEILI Perspective

From our extensive experience in guiding overseas registration projects, the most common misjudgment is not about the product itself, but the silent error of "I don't know what I don't know." Many small and medium-sized dental device companies hold only one domestic registration certificate and assume that mutual recognition can be achieved through "translation plus notarization." In reality, classification is the first gateway. If it fails, a perfect technical file cannot save the project.

In the early stages of a project, we recommend that companies treat classification determination as a milestone task. First, internal R&D and regulatory personnel derive candidate classifications based on the instructions and structural features. Then, through a local experienced agent, make informal inquiries with the regulatory authority. Only after receiving a written response should the company enter formal submission. This approach significantly reduces the risk of rework.

Regarding documentation, ISO 13485 and risk management reports are universally applicable foundations, and MDSAP certificates are valuable for GHWP multi-country registration. However, clinical data, labels and instructions, sterilization validation, and chemical testing often need to be localized. For example, some Southeast Asian countries have differences in chemical and electrical standards, while Middle Eastern countries may require additional temperature testing or material composition declarations.

A local agent is not just a signing tool. The agent's document management capabilities, communication channels with regulatory authorities, and understanding of classification determination determine the speed of project advancement. The control of certificates must remain in the company's own hands, with at least clear arrangements for master certificates and copies. The same applies to changes and renewals; do not wait until the certificate is about to expire to realize that the agent has left.

For multi-country registration, we recommend establishing a "classification-documentation-requirements" matrix. List the classification, standards, timeline, cost, and agent information of the same product in different countries as rows and columns. This allows you to see at a glance which test reports can be reused and which must be newly generated. This approach avoids redundant preparation for each country and prevents the omission of key evidence during corrections.

Frequently Asked Questions

Q1: Are dental implants always the highest risk category in GHWP member states?

In the vast majority of cases, yes, because dental implants are long-term implantable devices that come into direct contact with tissue and may have surface treatments or coatings. However, it is important to note that, for example, Indonesia and Malaysia may manage pure titanium implants in the same category as those with active coatings, but the review requirements may differ slightly. Companies should consult each country's classification table separately and not assume that all countries are the same.

Q2: Can CE classification be used directly as the basis for other countries' classifications?

No, they cannot be directly equated. CE MDR is based on European classification rules, while some GHWP countries use GHTF/IMDRF principles or local rules. For example, clear aligners may be Class IIa in the European Union, but in Saudi Arabia they may be classified as Class II or Class III. It is recommended to take local rules as the authoritative basis and use CE technical documentation as a reference, not as a classification conclusion.

Q3: If the classification is unclear, can we submit a registration application first and let the regulatory authority decide?

We do not recommend submitting hastily. Most countries provide pre-classification or "product classification consultation" channels, such as the "STAR" classification request in Saudi Arabia, ANVISA classification consultation in Brazil, and the CCS classification consultation in the UAE. Using these channels allows you to obtain an official written opinion, providing stability for the registration application. If you submit directly, you may be required to withdraw and resubmit due to classification mismatch, wasting time and money.

Continue Reading

Previous: Why Do Registration Timelines Extend for Implantable Products?

Next: How to Determine Product Classification for Rehabilitation Equipment Overseas Registration?

Recommended Reading:

• What Should Be Prepared Before Renewal of Monitoring Device Overseas Registration?
• How Are Authorized Representative Responsibilities Divided for Rehabilitation Equipment Overseas Registration?
• Why Do Registration Timelines Extend for Implantable Products?
• How to Determine Product Classification for Rehabilitation Equipment Overseas Registration?
• What Are the Common Reasons for Supplemental Documentation in Rehabilitation Equipment Overseas Registration?
• What Are the Requirements for Risk Management Files for Rehabilitation Equipment Overseas Registration?

Return to FAQ Center | News | Contact AIMEILI

Content Review and Applicability Boundaries

Content Author: AIMEILI Regulatory Editorial Team

Professional Review: AIMEILI Medical Device International Registration Project Team

Source Principle: Priority is given to official regulatory agencies, international organizations, standards organizations, and publicly available regulatory materials; industry media and project experience serve only as supplementary reference.

Applicability Boundary: This article is intended for preliminary understanding, documentation preparation, and project planning. It does not replace the official requirements, testing conclusions, or legal opinions of the target country's regulatory authorities.